Rare Disease Biotech CEO Cashes Out $35 Million Stake Amid M&A Completion

On April 27, upon completion of BioMarin’s acquisition of Amicus Therapeutics, Inc. (NASDAQ: FOLD), CEO Bradley L. Campbell converted all of his common shares and stock options to cash, realizing approximately $35 million (about KRW 470 billion) in total compensation. That same day, the company’s General Counsel and Chief Financial Officer also cashed out their equity holdings, stock options, and restricted stock units, each completing exits worth tens of millions of dollars (hundreds of billions of KRW). Regulatory filings show that none of the three executives retain any equity stake in Amicus following the acquisition.

BioMarin announced that it had acquired Amicus in an all-cash transaction valued at $14.50 per share, totaling $4.8 billion (approximately KRW 6.5 trillion), and that Amicus will become a wholly owned subsidiary. All Amicus common shares will be converted to cash, and related Nasdaq registration and listing processes will be phased out.

Amicus is a U.S. biotech company specializing in therapies for rare diseases such as Fabry and Pompe disorders, with products including the oral Fabry disease treatment Galafold and a combination therapy for Pompe disease. BioMarin, a global pharmaceutical firm focused on rare disease treatments, aims to expand its lysosomal storage disorder portfolio and revenue base through this acquisition.